Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib

Main Article Content

Melissa Peri Zundell
Icahn School of Medicine at Mount Sinai

Dr. Alexandra K. Golant
Icahn School of Medicine at Mount Sinai

Keywords

beard alopecia, alopecia barbae, Alopecia areata, baric, JAK inhibitor, treatment response

Abstract

Alopecia areata is an autoimmune disorder causing localized hair loss due to T-cell attack on hair follicles. Beard involvement holds psychological and cultural significance, and treatment guidance for steroid-resistant cases is limited. We present a case of the successful treatment of steroid-resistant beard alopecia areata (BAA) with baricitinib, a JAK-1/2 inhibitor, in a 37-year-old male. Prior therapies, including topical ruxolitinib and intralesional steroids, had failed. Over 9 months, baricitinib (4 mg daily) and oral minoxidil led to reduced alopecic patches, increased hair density, and resolved inflammation. This case underscores the potential of JAK inhibitors for BAA, emphasizing the importance of establishing clear guidelines to direct treatment of in order to optimize patient outcomes.

References

1. Cervantes, J., Fertig, R.M., Maddy, A. et al. Alopecia Areata of the Beard: A Review of the Literature. Am J Clin Dermatol 18, 789–796 (2017). https://doi.org/10.1007/s40257-017-0297-6

2. Moussa A, Eisman S, Sinclair RD, Bhoyrul B. Treatment of alopecia areata of the beard with baricitinib. J Am Acad Dermatol. 2023 Apr;88(4):948-950. doi: 10.1016/j.jaad.2022.11.028. Epub 2022 Nov 24. PMID: 36427662.

3. Smith P, Yao W, Shepard S, Covington M, Lee J, Lofland J, Naim A, Sheth T, Parikh B, Yeleswaram S. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics. 2021 Jul 8;13(7):1044. doi: 10.3390/pharmaceutics13071044. PMID: 34371735; PMCID: PMC8309120.

4. Saceda-Corralo D, Grimalt R, Fernández-Crehuet P, Clemente A, Bernárdez C, García-Hernandez MJ, Arias-Santiago S, Rodrigues-Barata AR, Rodríguez-Pichardo A, García-Lora E, Jaén P, Camacho FM, Vañó-Galván S. Beard alopecia areata: a multicentre review of 55 patients. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):187-192. doi: 10.1111/jdv.13896. Epub 2016 Sep 12. PMID: 27503140.

5. Ramot Y, Zlotogorski A. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient. Skin Appendage Disord. 2018 Apr;4(2):122-124. doi: 10.1159/000479722. Epub 2017 Sep 9. PMID: 29765973; PMCID: PMC5939711.

6. Kerkemeyer KLS, John JM, Sinclair R, Bhoyrul B. Response of alopecia areata of the beard to oral tofacitinib. J Am Acad Dermatol. 2020 May;82(5):1228-1230. doi: 10.1016/j.jaad.2019.10.058. Epub 2019 Oct 31. PMID: 31678329.

7. Abduelmula A, Mufti A, Mistry J, Sachdeva M, Beecker J, Prajapati VH, Yeung J. Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review. J Cutan Med Surg. 2023 Jan-Feb;27(1):73-75. doi: 10.1177/12034754221130243. Epub 2022 Oct 2. PMID: 36189927; PMCID: PMC9902965.

8. Kerkemeyer KLS, Sinclair RD, Bhoyrul B. Topical tofacitinib for the treatment of alopecia areata affecting facial hair. Br J Dermatol. 2021 Sep;185(3):677-679. doi: 10.1111/bjd.20419. Epub 2021 Jun 22. PMID: 33914907.

9. Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol. 2021 Sep;85(3):743-745. doi: 10.1016/j.jaad.2019.08.080. Epub 2019 Sep 6. PMID: 31499158.

Article Sidebar

PDF KOL SUMMARY
Published
Mar 18, 2024
DOI https://doi.org/10.25251/skin.8.2.14

Article Details

How to Cite
Zundell, M., & Golant, A. . (2024). Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib . SKIN The Journal of Cutaneous Medicine, 8(2), 1435–1438. https://doi.org/10.25251/skin.8.2.14
Issue
Vol. 8 No. 2 (2024): March 2024 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)